Mycophenolate mofetil: A unique immunosuppressive agent

American Journal of Health-System Pharmacy

Volumn 54, Issue 3, 1997, Pages 285-294

  Hood, Kerri A ^a   Zarembski, Dawn G ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Dosage; Immunosuppressive agents; Mechanism of action; Mycophenolate mofetil; Pharmacokinetics; Toxicity

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROBENECID;

BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CARCINOGENESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; REVIEW;

EID: 0031032634     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.3.285     Document Type: Review

References (43)

1. Gosio B. Ricerche bacteriologiche e chimiche sulle alterazioni del mais. Riv Ig Pubblica. 1896; 7:825-68.
2. Abraham EP. The effect of mycophenolic acid on the growth of Staphylococcus aureas in heart broth. Biochem J. 1945; 39:398-405.
3. Florey HW, Gilliver K, Jennings MA et al. Mycophenolic acid: an antibiotic from Penicillium brevicompactum. Lancet. 1946; 1:46-9.
4. Williams RH, Lively DH, Delong DC et al. Mycophenolic acid: antiviral and antitumor properties. J Antibiot. 1968; 21:463-4.
5. Carter SB, Franklin TJ, Jones DF et al. Mycophenolic acid: an anticancer compound with unusual properties. Nature. 1969; 223:848-50.
6. Suzuki S, Kimura T, Ando K et al. Antitumor activity of mycophenolic acid. J Antibiot. 1969; 22:297-302.
7. Brewin TB, Cole MP, Jones CTA et al. Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother Rep. 1972; 56:83-7.
8. Knudtzon S, Nissen NI. Clinical trial with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep. 1972; 56:221-7.
9. Lintrup J, Hyltoft-Petersen P, Knudtzon S et al. Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep. 1972; 56:229-35.
10. Taylor DO, Ensley RD, Olsen SL et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 1994; 13:571-82.
11. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective anti-proliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol. 1991; 33:175-83.
12. Eugui EM, Almquist S, Muller CD et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991; 33:161-73.
13. Allison AC, Hovi T, Watts RWE et al. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp. 1977; 48:207-24.
14. Gilbett ER, Anderson JE, Cohen F et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972; 2:1067-9.
15. Lee WA, Gu L, Miksztal AR et al. Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharm Res. 1990; 7:161-6.
16. Sollinger HW, Deierhoi MH, Belzer FO et al. RS-61443 - a Phase I clinical trial and pilot rescue study. Transplantation. 1992; 53:428-32.
17. Sollinger HW, Belzer FO, Deierhoi MH et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg. 1992; 216:513-8.
18. Klintman GB, Ascher NL, Busuttil RW et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc. 1993; 25:697.
19. Ensley RD, Bristow MR, Olsen SL et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation. 1993; 56:75-82.
20. Kirklin JK, Bourge RC, Naftel DC et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant. 1994; 13:444-50.
21. Kobashigawa JA, Renlund DG, Olsen SL et al. Initial results of RS-61443 for refractory cardiac rejection. J Am Coll Cardiol. 1992; 19:203A. Abstract.
22. Allison AC, Kowalski WJ, Muller CD et al. Mechanism of action of mycophenolic acid. Ann N Y Acad Sci. 1990; 696:63-87.
23. Young CJ, Sollinger HW. RS-61443: a new immunosuppressive agent. Transplant Proc. 1994; 26:3144-6.
24. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant. 1993; 7:96-112.
25. Cellcept package insert. Nutley, NJ: Roche Laboratories; 1995 May.
26. Sweeney MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res. 1972; 32:1803-9.
27. Deierhoi MH, Kauffman RS, Hudson SL et al. Experience with mycophenolate mofetil (RS-61443) in renal transplantation at a single center. Ann Surg. 1993; 217:476-84.
28. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995; 41:1011-7.
29. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem. 1995; 41:295-9.
30. Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Ther Drug Monit. 1994; 16:602-7.
31. Deierhoi MH, Sollinger HW, Diethelm AG et al. One-year follow up results of a Phase I trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc. 1993; 25:693-4.
32. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995; 60:225-32.
33. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 1995; 345:1321-5.
34. Freise CE, Hebert M, Osorio RW et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc. 1993; 25:1758-9.
35. Epinette WW, Parker CM, Jones EL et al. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987; 17:962-71.
36. Marinari R, Fleischmajer R, Schragger AH et al. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol. 1977; 113:930-2.
37. Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975; 65:537-42.
38. Lynch WS, Roenigk HH. Mycophenolic acid for psoriasis. Arch Dermatol. 1977; 113:1203-8.
39. Schiff MH, Goldblum R, Rees MMC. Mycophenolate mofetil (myco-M) effectively treats refractory rheumatoid arthritis (RA) patients for one year. Arthritis Rheum. 1990; 34S:89. Abstract.
40. Salaman JR, Griffin PJA, Johnson RWG et al. Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc. 1993; 25:695-6.
41. RS-61443 Investigation Committee - Japan. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc. 1995; 27:1421-4.
42. Laskow DA, Deierhoi MH, Hudson SL et al. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS-61443). Transplantation. 1994; 57:640-3.
43. Cardinale V, ed. Red book. Montvale, NJ: Medical Economics; 1996.